Steinberg Orna, Gilad Gil, Dgany Orly, Krasnov Tatyana, Zoldan Meira, Laor Ruth, Kapelushnik Joseph, Gabriel Herzel, Churi Chaim, Stein Jerry, Yaniv Isaac, Tamary Hannah
Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, Isreal.
J Pediatr Hematol Oncol. 2007 Dec;29(12):822-5. doi: 10.1097/MPH.0b013e318158152e.
Congenital amegakaryocytic thrombocytopenia (CAMT) is a rare bone marrow failure syndrome associated with thrombocytopenia and a tendency to progress to aplastic anemia. Mutations in the c-MPL gene encoding for thrombopoietin receptor have been identified in the majority of the patients. Previous studies suggest a genotype-phenotype correlation wherein the severity of the disease depends on the type of mutation present and residual thrombopoietin receptor activity. The present study describes the clinical and genetic findings on a series of 7 patients with CAMT, 3 of them siblings. The patients were homozygous for 5 mutations in the c-MPL gene, including 3 unique ones: c.212+5G>A, C76T, and G1162C. The clinical picture was variable; 1 patient who was homozygous for a nonsense mutation in exon 1 (C76T) developed infantile acute lymphoblastic leukemia, whereas patients who were homozygous for a splice-site mutation (c.212+5G>A) expressing both normal and mutated transcripts had a milder clinical course. As previously suggested, c-MPL mutation analysis in CAMT patients helps to predict the clinical course and to provide optimal therapy.
先天性无巨核细胞性血小板减少症(CAMT)是一种罕见的骨髓衰竭综合征,与血小板减少症相关,并有发展为再生障碍性贫血的倾向。在大多数患者中已发现编码血小板生成素受体的c-MPL基因突变。先前的研究表明存在基因型-表型相关性,即疾病的严重程度取决于存在的突变类型和残余血小板生成素受体活性。本研究描述了一系列7例CAMT患者的临床和基因研究结果,其中3例为兄弟姐妹。这些患者在c-MPL基因中有5种突变的纯合子,包括3种独特的突变:c.212+5G>A、C76T和G1162C。临床表现各不相同;1例在外显子1中存在无义突变(C76T)的纯合子患者发生了婴儿急性淋巴细胞白血病,而对于剪接位点突变(c.212+5G>A)表达正常和突变转录本均为纯合子的患者临床病程较轻。如先前所述,对CAMT患者进行c-MPL突变分析有助于预测临床病程并提供最佳治疗。